Zenapax, Ro 24-7375, Daclizumab, ILReceptor, IL-2, IL Receptor
Daclizumab (Zenapax) is a humanized monoclonal antibody targeting the CD25 alpha subunit of the IL-2 receptor, thereby blocking IL-2 binding. It has been investigated in research contexts, including in vitro assays and clinical studies for autoimmune conditions like multiple sclerosis, to modulate T-cell mediated immune responses.
Concentration:
19.92 mg/mL
Molecular Weight:
144.12 kDa
Purity:
100.00% (May vary between batches)
CAS Number:
[152923-56-3]
Target:
IL Receptor,Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted